Login to Your Account



Synta's Interim GALAXY Data Encouraging Despite Stock Fall

By Catherine Shaffer
Staff Writer

Wednesday, August 8, 2012

Positive interim results from its GALAXY trial of ganetespib and docetaxel for non-small-cell lung cancer (NSCLC) ran Synta Pharmaceuticals Corp.'s stock price off a cliff Thursday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription